Shuuichi Mori, Masahiko Kishi, Sachiho Kubo, Takuyu Akiyoshi, Shigeru Yamada, Tsuyoshi Miyazaki, Tetsuro Konishi, Naoki Maruyama, Kazuhiro Shigemoto
Index: J. Neuroimmunol. 245(1-2) , 75-8, (2012)
Full Text: HTML
This study investigated the effect of 3,4-diaminopyridine (3,4-DAP), a potent potentiator of transmitter release, on neuromuscular transmission in vivo in a mouse model of myasthenia gravis (MG) caused by antibodies against muscle-specific kinase (MuSK; MuSK-MG) and ex vivo in diaphragm muscle from these mice. 3,4-DAP significantly improved neuromuscular transmission, predominantly by increasing acetylcholine (ACh) release, supporting presynaptic potentiation as an effective treatment strategy for MuSK-MG patients who have defective transmitter release. In MuSK-MG, we suggest that only low-dose acetylcholinesterase (AChE) inhibitors be used to avoid side effects, and we propose that 3,4-DAP may be effective as a symptomatic therapy.Copyright © 2012 Elsevier B.V. All rights reserved.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
3,4-Diaminopyridine
CAS:54-96-6 |
C5H7N3 |
Novel HPLC--Fluorescence methodology for the determination o...
2015-11-15 [Food Chem. 187 , 159-65, (2015)] |
Ectopic uterine tissue as a chronic pain generator.
2012-12-06 [Neuroscience 225 , 269-82, (2012)] |
3-D-QSAR and docking studies on the neuronal choline transpo...
2010-08-15 [Bioorg. Med. Chem. Lett. 20 , 4870-7, (2010)] |
Acute and chronic effects of botulinum neurotoxin a on the m...
2014-08-01 [Muscle Nerve 50(2) , 206-15, (2014)] |
Orphan drugs. BioMarin Europe replies.
2010-01-01 [BMJ 341 , c7006, (2010)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved